Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

Circulation

Volumn 105, Issue 21, 2002, Pages 2469-2475

  Gagné, Claude ^a   Gaudet, Daniel ^a   Bruckert, Eric ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Cholesterol; Hypercholesterolemia; Lipids; Lipoproteins; Statins

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADOLESCENT; ADULT; AGED; APHERESIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; GENOTYPE; HOMOZYGOTE; HUMAN; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD;

ADOLESCENT; ADULT; ANTICHOLESTEREMIC AGENTS; ARTERIOSCLEROSIS; AZETIDINES; BLOOD COMPONENT REMOVAL; CHILD; CHOLESTEROL, LDL; CREATINE KINASE; DIET THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIVER FUNCTION TESTS; MALE; PYRROLES; SIMVASTATIN; TREATMENT OUTCOME;

EID: 0037188567     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000018744.58460.62     Document Type: Article

References (35)

1. Familial hypercholesterolemia
2. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolemia
3. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesteremia
4. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1
5. Evidence for a third genetic locus causing familial hypercholesterolemia: A non-LDLR, non-APOB kindred
6. Genetic localization to chromosome 1p32 of the third genetic locus for familial hypercholesterolemia in Utah kindred
7. Relationships of abnormal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene
8. Mutations of low-density-lipoprotein-receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolaemia
9. Software and database for the analysis of mutations in the human LDL receptor gene
10. Familial hypercholesterolemia
11. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia
12. Liver transplantation in patients with homozygotic familial hypercholesterolemia previously treated by end-to-side portocaval shunt and ileal bypass
13. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
14. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
15. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function
16. Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects
17. Drug therapy for hypercholesterolemia and dyslipidemia
18. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: Pooled analysis of two phase II studies
19. An investigative look: Selective cholesterol absorption inhibitors-embarking on a new standard of care
20. Novel approaches to lipid lowering: What is on the horizon?
21. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
22. Cholesterol absorption inhibition: Filling an unmet need in lipid-lowering management
23. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs
24. The recognition and management of hyperlipidaemia in adults: A policy statement of the European Atherosclerosis Society
25. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
26. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
27. Low-density lipoprotein receptor gene mutations in a Southeast Asian population with familial hypercholesterolemia
28. A rapid procedure for extracting genomic DNA from leukocytes
29. Molecular genetic testing for familial hypercholesterolemia: Spectrum of LDL receptor gene mutations in the Netherlands
30. An efficient screening procedure detecting six novel mutations in the LDL receptor gene in Swedish children with hypercholesterolemia
31. Using mutagenic polymerase chain reaction primers to detect carriers of familial defective apolipoprotein B-100
32. Clinical signs of familial hypercholesterolemia in patients with familial defective apolipoprotein B-100 and normal low density lipoprotein receptor function
33. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia
34. LDLR Database (second edition): New additions to the database and the software, and results of the first molecular analysis